Meeting
2024 ASCO Annual Meeting
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).
Authors
Bunpei Miyazaki
Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
Bunpei Miyazaki , Nami Shirakawa , Minako Sugiyama , Ayumu Arakawa , Yayoi Ando , Kenta Anjo , Yoko Kai , Yukari Hoshina , Junki Mizusawa , Taro Shibata , Haruhiko Fukuda , Natsuko Tsuda Okita , Kenichi Nakamura , Chitose Ogawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
jRCTs031230544
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS10079)
DOI
10.1200/JCO.2024.42.16_suppl.TPS10079
Abstract #
TPS10079
Poster Bd #
445a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
First Author: Arthur Geraud
Poster
2023 ASCO Annual Meeting
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.
First Author: Yayoi Ando
Poster
2022 ASCO Annual Meeting
AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.
First Author: Omar Saavedra Santa Gadea
Poster
2018 ASCO Annual Meeting
A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.
First Author: Karen Kelly